| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910765494303321 |
|
|
Autore |
Matson Johnny L |
|
|
Titolo |
Clinical Handbook of ADHD Assessment and Treatment Across the Lifespan |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham : , : Springer International Publishing AG, , 2023 |
|
©2023 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (655 pages) |
|
|
|
|
|
|
Collana |
|
Autism and Child Psychopathology Series |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Trastorns per dèficit d'atenció amb hiperactivitat en els infants |
Trastorns per dèficit d'atenció amb hiperactivitat en els adults |
Llibres electrònics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Contents -- About the Editor -- 1: ADHD in Culturally and Linguistically Diverse Children -- 1.1 Establishing an Ecological Perspective on ADHD -- 1.2 Sociocultural Risk Factors at the Child Level -- 1.3 Sociocultural Risk Factors at the Microsystem -- 1.4 Exosystem-Level Risk Factors -- 1.5 Macrolevel Risk Factors -- 1.6 Methodological and Conceptual Challenges in Studying ADHD Among Culturally and Linguistically Diverse Children -- 1.7 Concluding Remarks -- References -- 2: Gender Differences in Adults with ADHD -- 2.1 ADHD in Adulthood -- 2.1.1 Presentation of Adult ADHD -- 2.1.2 Impairments in Adult ADHD -- 2.2 Gender Differences in ADHD -- 2.2.1 Theories of Gender Differences in ADHD -- 2.2.2 Gender Differences in ADHD Presentation -- 2.3 Symptoms and Impairments Among Women with ADHD -- 2.3.1 Social Difficulties, Romantic Relationships, and Motherhood -- 2.3.2 Emotion Dysregulation -- 2.3.3 Self-Esteem and Internalizing Problems -- 2.3.4 Sexual Behaviors -- 2.4 Assessment and Diagnosis of Adult ADHD -- 2.4.1 Self-Report and Retrospective Recall of Symptoms -- 2.4.2 Symptoms Relevant to Adult ADHD -- 2.5 Treatment -- 2.5.1 Medication Treatment -- 2.5.1.1 Stimulant Misuse -- 2.5.1.2 Pharmacotherapy and Women with ADHD -- 2.5.2 Psychosocial Interventions -- 2.6 Future Directions -- 2.6.1 Expanding Knowledge of Adult ADHD Beyond 25 -Year-Old White |
|
|
|
|
|
|
|
|
|
Men -- 2.6.2 ADHD in the Transgender, Non-Binary, and Gender Non-Conforming Population -- 2.7 Conclusion -- References -- 3: Autonomic Nervous System Functioning in ADHD -- 3.1 Introduction -- 3.2 Arousal and the Autonomic Nervous System -- 3.2.1 Structural Components of the Autonomic Nervous System -- 3.2.2 Indices of Autonomic Nervous System Functioning in Humans -- 3.2.3 The Role of the Autonomic Nervous System in Cognition and Self-Regulation. |
3.2.4 Development of the Autonomic Nervous System in Humans -- 3.3 Theoretical Models of Autonomic Nervous System Dysfunction in ADHD -- 3.4 Evidence of Dysregulation of the Autonomic Nervous System in ADHD -- 3.4.1 Salivary Alpha-Amylase and Cortisol -- 3.4.2 Peripheral Indices of Autonomic Nervous System Functioning -- 3.4.2.1 Evidence from Systematic Reviews and Meta-analysis -- 3.4.2.2 Evidence from Recent Studies on Cardiovascular Measures and Electrodermal Activity -- Resting State -- Cognitive Tasks and Reward Processing -- Socioemotional Tasks -- 3.4.2.3 Evidence from Recent Studies on Pupil Size -- 3.4.3 Functioning of the Enteric Nervous System and the Gut-Brain Axis in ADHD -- 3.4.4 Summary of Studies Investigating Autonomic Functioning in ADHD -- 3.5 Autonomic Dysregulation and Co-occurring Psychiatric Symptoms in ADHD -- 3.5.1 Oppositional Defiant Disorder and Conduct Disorder -- 3.5.2 Autism Spectrum Disorder -- 3.5.3 Mood Disorder and Emotional Dysregulation -- 3.5.4 Sluggish-Cognitive Tempo -- 3.6 Effects of Pharmacological and Nonpharmacological Interventions for ADHD on Autonomic Nervous System Functioning -- 3.7 Implications and Future Directions -- 3.7.1 Theoretical Models of ADHD -- 3.7.2 Implications for Clinical Practice -- 3.7.3 Open Questions for Future Research -- 3.8 Conclusions -- References -- 4: Effects of Alertness and Inhibitory Control on Adults with ADHD -- 4.1 Introduction -- 4.2 Everyday Life Experiences of Difficulties with Alertness and Inhibitory Control -- 4.3 Behavioural Evidence of Difficulties Associated with Alertness and Inhibitory Control -- 4.4 Cognitive Evidence of Difficulties Associated with Alertness and Inhibitory Control -- 4.5 Theoretical Perspectives on Alertness and Inhibitory Control -- 4.6 Neurobiological Evidence of Alertness and Inhibitory Control. |
4.7 Targeted Therapies for Alertness and Inhibitory Control -- 4.8 Conclusion -- References -- 5: Executive Functions and Emotional Lability in Adults with ADHD -- 5.1 ADHD -- 5.2 Comorbidity -- 5.3 Executive Functions and ADHD -- 5.4 Emotional Dysregulation and ADHD -- 5.5 Additive Effect of Executive Function Deficits and Emotion Dysregulation in ADHD -- 5.6 Assessment and Treatment of ADHD and Related Difficulties in EF and ED -- 5.6.1 Cognitive EF Assessment: Cold and Hot Neuropsychological Measures -- 5.6.2 Behavioral EF Assessment: Behavioral Rating Scales -- 5.7 Assessment of Emotional Dysregulation Symptoms -- 5.8 Treatment -- 5.8.1 Executive Functioning -- 5.8.2 Emotional Dysregulation -- References -- 6: Cognitive Event-Related Potentials and ADHD Across the Lifespan -- 6.1 Introduction -- 6.2 Event-Related Potentials (ERPs) -- 6.3 ERPs as Putative Neurophysiological Markers for ADHD -- 6.4 ADHD and ERPs Usefulness -- 6.4.1 Earlier ERPs -- 6.4.1.1 P50 -- Children and Adolescents -- Adults -- 6.4.1.2 P100 -- Children and Adolescents -- Adults -- 6.4.1.3 N100 -- Children and Adolescents -- Adults -- 6.4.1.4 Error-Related Negativity (ERN/Ne) -- Children and Adolescents -- Adults -- 6.4.1.5 P200 -- P200 in Children/Adolescents -- Children and Adolescents -- Adults -- 6.4.1.6 Mismatch Negativity (MMN) -- Children and Adolescents -- Adults -- 6.4.1.7 N200 -- Children and Adolescents -- Adults -- 6.4.2 Later Cognitive Event-Related Potential -- 6.4.2.1 P300 -- Children and Adolescents -- Adults -- 6.4.2.2 |
|
|
|
|
|
|
|
Contingent Negative Variation (CNV) -- Children and Adolescents -- Adults -- 6.5 ERP Putative Biomarkers and Brain Maturation Across Lifespan -- 6.6 Final Remarks -- References -- 7: Adult Persons with ADHD and Their Lifestyle -- 7.1 Introduction -- 7.2 Living with ADHD -- 7.2.1 Cognitive Impairments Limit Daily Life -- 7.2.2 Lifestyle Factors. |
7.2.2.1 Drug Use and Poor Diet -- 7.2.2.2 Alcohol and Drug Abuse -- 7.2.3 Major Morbidity with Both Physical and Mental Illness -- 7.2.4 Problems with Social Relationships and Loneliness -- 7.2.5 Deteriorated Quality of Life -- 7.2.6 Combined Treatments Are Needed -- 7.3 Lifestyle Interventions Are Important to Improve Life Situation -- 7.3.1 Experiences of Lifestyle Interventions -- 7.3.1.1 Social Support and Motivation Are Needed -- 7.3.2 Need for More Health-Promoting Lifestyle Interventions for Persons with ADHD -- 7.3.2.1 Interpersonal Relationships Affect Health -- 7.3.3 A Nurse-Led Lifestyle Intervention -- 7.3.3.1 The Theoretical Basis of the Intervention -- Interpersonal Relationships -- Health Education and Health Information -- Individual Support -- Social and Practical Support -- 7.4 Conclusion -- References -- 8: Teacher Knowledge of ADHD in Children -- 8.1 Introduction -- 8.2 Impact of ADHD in the Classroom -- 8.3 Importance of the Teacher´s Role for Children with ADHD -- 8.4 Teacher Knowledge -- 8.5 Consequences of Poor Teacher Knowledge -- 8.6 How Is Teacher Knowledge of ADHD Measured? -- 8.7 The Extent of Teacher Knowledge -- 8.7.1 Teacher Knowledge in the Middle East -- 8.7.2 Teacher Knowledge in the United Kingdom (UK) -- 8.7.3 Teacher Knowledge in Australia -- 8.8 Factors that Affect Teacher Knowledge -- 8.9 Conclusion and Future Recommendations -- References -- 9: Environmental Risk Factors for Attention-Deficit/Hyperactivity Disorder -- 9.1 Introduction -- 9.2 Prenatal Risk Factors for ADHD -- 9.2.1 Maternal Mental Health -- 9.2.1.1 Maternal Distress -- 9.2.2 Maternal Physical Health -- 9.2.2.1 Maternal Nutrition -- 9.2.2.2 Gestational Anemia -- 9.2.2.3 Pre-pregnancy Maternal BMI and Obesity -- 9.2.2.4 Hypertensive Disorders and Preeclampsia -- 9.2.2.5 Maternal Diabetes -- 9.2.3 Maternal Medication and Substance Use. |
9.2.3.1 Antidepressants and Other Neuropsychiatric Medications -- 9.2.3.2 Caffeine, Alcohol, and Smoking -- 9.2.3.3 Opioids, Cocaine, and Methamphetamine -- 9.2.3.4 Polysubstance Use -- 9.2.4 Maternal Exposure to Environmental Toxins -- 9.2.4.1 Lead -- 9.2.4.2 Mercury -- 9.2.4.3 Polychlorinated Biphenyls (PCBs) -- 9.2.4.4 Air Pollution and Other Commonly Encountered Toxins -- 9.3 Perinatal and Childbirth-Related Factors -- 9.3.1 Parental Age at Childbirth -- 9.3.2 Prematurity and Low Birth Weight -- 9.3.3 Method of Delivery and Labor Induction -- 9.3.4 Postnatal Factors -- 9.3.4.1 Exposure to Environmental Toxins -- 9.3.4.2 Psychosocial Factors -- 9.3.4.3 Nutrition -- 9.4 Gene-Environment Interaction -- 9.5 Protective Factors -- 9.6 Summary and Future Considerations -- References -- 10: ADHD and Sleep Problems -- 10.1 Sleep and ADHD -- 10.1.1 What Is Sleep and How Does It Work? -- 10.1.2 What Do We Know About Sleep in Individuals with ADHD? -- 10.1.3 Are There Any Differences in the Circadian Rhythm of Individuals with ADHD? -- 10.1.4 What Can We Conclude About Sleep in Individuals with ADHD? -- 10.1.5 What Is the Impact of Poor Sleep? -- 10.2 Assessment of Sleep -- 10.2.1 What Are the Most Common Assessment Tools? -- 10.2.2 What Is the Suggested Approach to the Assessment of Sleep? -- 10.2.2.1 Step 1: Screening -- 10.2.2.2 Step 2: Clinical Assessment -- 10.2.2.3 Step 3 (If Required): Sleep Specialist Assessment -- 10.2.2.4 Step 4: Monitoring and Follow-Up -- 10.2.3 What Considerations Need to Be Made for Individuals with ADHD? -- |
|
|
|
|
|
|
|
|
10.3 Sleep Disorders and Treatment -- 10.3.1 Insomnia -- 10.3.1.1 What Is Insomnia Disorder, Its Prevalence, Etiology, and Impacts? -- 10.3.1.2 How Is Insomnia Disorder Assessed and Treated? -- 10.3.1.3 What About the Treatment of Insomnia in Individuals with ADHD? -- 10.3.2 Delayed Sleep-Wake Phase Disorder (DSWPD). |
10.3.2.1 What Is DSWPD, Its Prevalence, Etiology, and Impacts?. |
|
|
|
|
|
| |